Cargando…

A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex

Amrubicin is a novel, completely synthetic 9‐aminoanthracycline derivative. Amrubicin and its C‐13 alcohol metabolite, amrubicinol, inhibited purified human DNA topoisomerase II (topo II). Compared with doxorubicin (DXR), amrubicin and amrubicinol induced extensive DNA‐protein complex formation and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanada, Mitsuharu, Mizuno, Satoko, Fukushima, Akihisa, Saito, Yoshikazu, Noguchi, Toshihiro, Yamaoka, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 1998
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921721/ https://www.ncbi.nlm.nih.gov/pubmed/9914793 http://dx.doi.org/10.1111/j.1349-7006.1998.tb00519.x

Ejemplares similares

Uptake and Intracellular Distribution of Amrubicin, a Novel 9‐Amino‐anthracycline, and Its Active Metabolite Amrubicinol in P388 Murine Leukemia Cells
por: Yamaoka, Takashi, et al.
Publicado: (1999)

Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells
por: Yamaoka, Takashi, et al.
Publicado: (1998)

Tumor‐selective Distribution of an Active Metabolite of the 9‐Aminoanthracycline Amrubicin
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

In vivo Efficacy and Tumor‐selective Metabolism of Amrubicin to Its Active Metabolite
por: Noguchi, Toshihiro, et al.
Publicado: (1998)

Clinical significance of topoisomerase‐II expression in patients with advanced non‐small cell lung cancer treated with amrubicin
por: Sakurai, Reiko, et al.
Publicado: (2020)

Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis
por: Hanada, Mitsuharu, et al.
Publicado: (2008)

Identification of Novel 4′-O-Demethyl-epipodophyllotoxin Derivatives as Antitumor Agents Targeting Topoisomerase II
por: Xi, Wenli, et al.
Publicado: (2022)

Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study
por: Ikeda, Takaya, et al.
Publicado: (2020)

Inhibition of Topoisomerase II by a Novel Antitumor Cyclic Depsipeptide, BE‐22179
por: Yoshinari, Tomoko, et al.
Publicado: (1994)

Influencing factors of efficacy and long‐term use of amrubicin in patients with small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2023)

Premature phase II study of amrubicin as palliative chemotherapy for previously treated malignant pleural mesothelioma
por: Watanabe, Kageaki, et al.
Publicado: (2021)

In vitro Antitumor Activity of TAS‐103, a Novel Quinoline Derivative That Targets Topoisomerases I and II
por: Aoyagi, Yoshimi, et al.
Publicado: (1999)

Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma
por: Ando, Takayuki, et al.
Publicado: (2015)

Phase II study of nedaplatin and amrubicin as first‐line treatment for advanced squamous cell lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II
por: Molinaro, Caroline, et al.
Publicado: (2020)

Amrubicin is effective against small cell carcinoma of the prostate as a second‐line chemotherapeutic agent: A case report
por: Maesaka, Fumisato, et al.
Publicado: (2019)

Review of the Management of Relapsed Small-Cell Lung Cancer with Amrubicin Hydrochloride
por: Kimura, Tatsuo, et al.
Publicado: (2011)

Pneumothorax triggered by the combination of gefitinib and amrubicin and treated with endobronchial silicone spigots
por: Imamura, Fumio, et al.
Publicado: (2015)

Potential Activity of Amrubicin as a Salvage Therapy for Merkel Cell Carcinoma
por: Sakaida, Emiko, et al.
Publicado: (2017)

Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4′-demethylepipodophyllotoxin
por: Sun, Lin-Yang, et al.
Publicado: (2018)

Next-generation anthracycline for the management of small cell lung cancer: focus on amrubicin
por: Yamamoto, Michiko, et al.
Publicado: (2009)

Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer
por: Ogawara, Daiki, et al.
Publicado: (2010)

Effective Monotherapy with Amrubicin for a Refractory Extrapulmonary Small-Cell Carcinoma of the Liver
por: Isobe, Taichi, et al.
Publicado: (2009)

Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer
por: Ding, Qian, et al.
Publicado: (2013)

Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II
por: Utsugi, Teruhiro, et al.
Publicado: (1997)

Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
por: Cowell, Ian G., et al.
Publicado: (2012)

A Mini Review of Novel Topoisomerase II Inhibitors as Future Anticancer Agents
por: Okoro, Cosmas O., et al.
Publicado: (2023)

A retrospective study of amrubicin monotherapy for the treatment of relapsed small cell lung cancer in elderly patients
por: Imai, Hisao, et al.
Publicado: (2017)

Menogaril, an Anthracycline Derivative, Inhibits DNA Topoisomerase II by Stabilizing Cleavable Complexes
por: Ono, Katsuhiro, et al.
Publicado: (1992)

Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients
por: Horita, Nobuyuki, et al.
Publicado: (2016)

MSN8C: A Promising Candidate for Antitumor Applications as a Novel Catalytic Inhibitor of Topoisomerase II
por: Ou, Jie-Bin, et al.
Publicado: (2023)

Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer
por: Makino, Yoshinori, et al.
Publicado: (2019)

Efficacy and safety of amrubicin therapy after chemoimmunotherapy in small cell lung cancer patients
por: Kushiro, Kohei, et al.
Publicado: (2022)

Antitumor Activities of a Novel 9‐Aminoanthracycline (SM‐5887) against Mouse Experimental Tumors and Human Tumor Xenografts
por: Morisada, Shinya, et al.
Publicado: (1989)

Secondary Leukemia Associated with the Anti-Cancer Agent, Etoposide, a Topoisomerase II Inhibitor
por: Ezoe, Sachiko
Publicado: (2012)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

Roles of the C-terminal domains of topoisomerase IIα and topoisomerase IIβ in regulation of the decatenation checkpoint
por: Kozuki, Toshiyuki, et al.
Publicado: (2017)

Incremental low doses of amrubicin for the treatment of bone marrow metastasis in small cell lung cancer
por: Asai, Nobuhiro, et al.
Publicado: (2013)

Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited‐disease small cell lung cancer
por: Sekine, Ikuo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kh5se6u4kgs1cd75j2shofkm5a